Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study.
Vazquez B, Wheless J, Desai J, Rabinowicz AL, Carrazana E. Vazquez B, et al. Among authors: carrazana e. Epilepsy Behav. 2021 May;118:107898. doi: 10.1016/j.yebeh.2021.107898. Epub 2021 Mar 19. Epilepsy Behav. 2021. PMID: 33752044 Free article. Clinical Trial.
Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study.
Hogan RE, Tarquinio D, Sperling MR, Klein P, Miller I, Segal EB, Rabinowicz AL, Carrazana E. Hogan RE, et al. Among authors: carrazana e. Epilepsia. 2020 May;61(5):935-943. doi: 10.1111/epi.16506. Epub 2020 Apr 27. Epilepsia. 2020. PMID: 32338380 Free PMC article. Clinical Trial.
Lack of observed tolerance to diazepam nasal spray (Valtoco®) after long-term rescue therapy in patients with epilepsy: Interim results from a phase 3, open-label, repeat-dose safety study.
Cascino GD, Tarquinio D, Wheless JW, Hogan RE, Sperling MR, Liow K, Desai J, Davis C, Rabinowicz AL, Carrazana E; DIAZ.001.05 Study Group. Cascino GD, et al. Among authors: carrazana e. Epilepsy Behav. 2021 Jul;120:107983. doi: 10.1016/j.yebeh.2021.107983. Epub 2021 May 3. Epilepsy Behav. 2021. PMID: 33957437 Free article. Clinical Trial.
Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.
Miller I, Wheless JW, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E; DIAZ.001.05 Study Group. Miller I, et al. Among authors: carrazana e. Epilepsia Open. 2021 Sep;6(3):504-512. doi: 10.1002/epi4.12494. Epub 2021 May 13. Epilepsia Open. 2021. PMID: 34033266 Free PMC article. Clinical Trial.
130 results